By using antibodies from a human donor with a self-induced hyper-immunity to snake venom, scientists have developed the most ...

Abstract Number: CT262 Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models Presenter: John M. Maris, MD ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral ...

today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR ...

Peripheral nerve injury triggers synaptic remodeling. The ganglioside GT1b stabilizes spinal excitatory synapses by ...

The Company’s clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information ...

Partnered Assets: SIRPα antagonists BI 765063 and BI 770371, an improved next generation SIRPα inhibitor, developed in partnership with Boehringer Ingelheim: Rapid Oral Abstracts of the Phase 1 ...

CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts ...

Biohaven (BHVN) announced that it will present 13 abstracts at the 2025 American ... TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer ...

Introduction: Cardiac fibrosis is one of the major pathophysiologic features of ischemic cardiac disorders and substantial evidence has shown that cardiac fibroblasts and their activated form ...